{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T02:42:34Z","timestamp":1782960154652,"version":"3.54.5"},"reference-count":34,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000050","name":"National Heart Lung and Blood Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100018138","name":"Kuni Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100018138","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplantation and Cellular Therapy"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1016\/j.jtct.2024.05.016","type":"journal-article","created":{"date-parts":[[2024,5,18]],"date-time":"2024-05-18T12:12:24Z","timestamp":1716034344000},"page":"774.e1-774.e12","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Optimizing Autologous Stem Cell Transplantation in Multiple Myeloma: The Impact of Intensive Chemomobilization"],"prefix":"10.1016","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1010-4578","authenticated-orcid":false,"given":"Andrew J.","family":"Portuguese","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3455-7360","authenticated-orcid":false,"given":"Albert C.","family":"Yeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3781-5441","authenticated-orcid":false,"given":"Rahul","family":"Banerjee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leona","family":"Holmberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalie","family":"Wuliji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0477-1446","authenticated-orcid":false,"given":"Damian J.","family":"Green","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5680-8688","authenticated-orcid":false,"given":"Marco","family":"Mielcarek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ajay K.","family":"Gopal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ted","family":"Gooley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip","family":"Stevenson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew J.","family":"Cowan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.jtct.2024.05.016_bib0001","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1182\/blood.2020005288","article-title":"Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial","volume":"136","author":"Voorhees","year":"2020","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.jtct.2024.05.016_bib0002","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1038\/bmt.2009.176","article-title":"CR represents an early index of potential long survival in multiple myeloma","volume":"45","author":"Wang","year":"2010","journal-title":"Bone Marrow Transplant"},{"issue":"10","key":"10.1016\/j.jtct.2024.05.016_bib0003","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1007\/s00277-018-3370-1","article-title":"Autologous stem cell transplantation in first remission is associated with better progression-free survival in multiple myeloma","volume":"97","author":"Aggarwal","year":"2018","journal-title":"Ann Hematol"},{"issue":"35","key":"10.1016\/j.jtct.2024.05.016_bib0004","doi-asserted-by":"crossref","first-page":"5775","DOI":"10.1200\/JCO.2008.17.9721","article-title":"Influence of pre- and post-transplantation responses on outcome of patients with multiple myeloma: sequential improvement of response and achievement of complete response are associated with longer survival","volume":"26","author":"Lahuerta","year":"2008","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.jtct.2024.05.016_bib0005","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1038\/sj.bmt.1705307","article-title":"Predictive factors for survival in myeloma patients who undergo autologous stem cell transplantation: a single-centre experience in 211 patients","volume":"37","author":"O'Shea","year":"2006","journal-title":"Bone Marrow Transplant"},{"issue":"31","key":"10.1016\/j.jtct.2024.05.016_bib0006","doi-asserted-by":"crossref","first-page":"4933","DOI":"10.1200\/JCO.2007.11.7879","article-title":"Relationship between depth of response and outcome in multiple myeloma","volume":"25","author":"Dingli","year":"2007","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.jtct.2024.05.016_bib0007","doi-asserted-by":"crossref","first-page":"e616","DOI":"10.1016\/S2352-3026(19)30167-X","article-title":"Response-adapted intensification with cyclophosphamide, bortezomib, and dexamethasone versus no intensification in patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trial","volume":"6","author":"Jackson","year":"2019","journal-title":"Lancet Haematol"},{"issue":"2","key":"10.1016\/j.jtct.2024.05.016_bib0008","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.bbmt.2014.10.023","article-title":"Impact of pretransplant therapy and depth of disease response before autologous transplantation for multiple myeloma","volume":"21","author":"Vij","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"issue":"9","key":"10.1016\/j.jtct.2024.05.016_bib0009","doi-asserted-by":"crossref","first-page":"770.e1","DOI":"10.1016\/j.jtct.2021.06.016","article-title":"The efficacy and safety of chemotherapy-based stem cell mobilization in multiple myeloma patients who are poor responders to induction: the mayo clinic experience","volume":"27","author":"Vaxman","year":"2021","journal-title":"Transplant Cell Ther"},{"issue":"7","key":"10.1016\/j.jtct.2024.05.016_bib0010","doi-asserted-by":"crossref","first-page":"590.e1","DOI":"10.1016\/j.jtct.2021.04.016","article-title":"Stem cell mobilization in multiple myeloma: comparing safety and efficacy of cyclophosphamide +\/- plerixafor versus granulocyte colony-stimulating factor +\/- plerixafor in the lenalidomide era","volume":"27","author":"Johnsrud","year":"2021","journal-title":"Transplant Cell Ther"},{"issue":"9","key":"10.1016\/j.jtct.2024.05.016_bib0011","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1016\/j.clml.2020.04.002","article-title":"KRD-PACE mobilization for multiple myeloma patients with significant residual disease before autologous stem-cell transplantation","volume":"20","author":"Cowan","year":"2020","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"3","key":"10.1016\/j.jtct.2024.05.016_bib0012","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1002\/jca.21360","article-title":"Cyclophosphamide-based hematopoietic stem cell mobilization before autologous stem cell transplantation in newly diagnosed multiple myeloma","volume":"30","author":"Tuchman","year":"2015","journal-title":"J Clin Apher"},{"issue":"5","key":"10.1016\/j.jtct.2024.05.016_bib0013","doi-asserted-by":"crossref","first-page":"384","DOI":"10.3816\/CLM.2006.n.014","article-title":"Cyclophosphamide mobilization does not improve outcome in patients receiving stem cell transplantation for multiple myeloma","volume":"6","author":"Dingli","year":"2006","journal-title":"Clin Lymphoma Myeloma"},{"issue":"2","key":"10.1016\/j.jtct.2024.05.016_bib0014","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/j.bbmt.2017.10.008","article-title":"Chemotherapy-based stem cell mobilization does not result in significant paraprotein reduction in myeloma patients in the era of novel induction regimens","volume":"24","author":"Oyekunle","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"issue":"12","key":"10.1016\/j.jtct.2024.05.016_bib0015","doi-asserted-by":"crossref","first-page":"e512","DOI":"10.1038\/bcj.2016.117","article-title":"Risk stratification in myeloma by detection of circulating plasma cells prior to autologous stem cell transplantation in the novel agent era","volume":"6","author":"Chakraborty","year":"2016","journal-title":"Blood Cancer J"},{"issue":"7","key":"10.1016\/j.jtct.2024.05.016_bib0016","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1016\/j.bbmt.2018.02.017","article-title":"Circulating plasma cells at the time of collection of autologous PBSC for transplant in multiple myeloma patients is a negative prognostic factor even in the age of post-transplant maintenance therapy","volume":"24","author":"Cowan","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"issue":"2","key":"10.1016\/j.jtct.2024.05.016_bib0017","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1080\/10428194.2016.1201572","article-title":"Impact of pre-transplant bone marrow plasma cell percentage on post-transplant response and survival in newly diagnosed multiple myeloma","volume":"58","author":"Chakraborty","year":"2017","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.jtct.2024.05.016_bib0018","article-title":"Bone marrow plasma cell assessment before peripheral blood stem cell mobilization in patients with multiple myeloma undergoing autologous stem cell transplantation","volume":"2014","author":"Lee","year":"2014","journal-title":"Biomed Res Int"},{"issue":"7","key":"10.1016\/j.jtct.2024.05.016_bib0019","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1111\/j.1349-7006.2007.00499.x","article-title":"Serum M-spike and transplant outcome in patients with multiple myeloma","volume":"98","author":"Dingli","year":"2007","journal-title":"Cancer Sci"},{"issue":"10","key":"10.1016\/j.jtct.2024.05.016_bib0020","doi-asserted-by":"crossref","first-page":"2033","DOI":"10.1038\/leu.2015.118","article-title":"Utility of serum free light chain measurements in multiple myeloma patients not achieving complete response to therapy","volume":"29","author":"Alhaj Moustafa","year":"2015","journal-title":"Leukemia"},{"issue":"8","key":"10.1016\/j.jtct.2024.05.016_bib0021","doi-asserted-by":"crossref","first-page":"3378","DOI":"10.1182\/blood-2005-07-2922","article-title":"Absolute values of immunoglobulin free light chains are prognostic in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantation","volume":"107","author":"Dispenzieri","year":"2006","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.jtct.2024.05.016_bib0022","doi-asserted-by":"crossref","first-page":"e77","DOI":"10.1016\/j.clml.2017.10.008","article-title":"Modified HyperCVAD versus bortezomib-HyperCAD in patients with relapsed\/refractory multiple myeloma","volume":"18","author":"Saraceni","year":"2018","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"12","key":"10.1016\/j.jtct.2024.05.016_bib0023","doi-asserted-by":"crossref","first-page":"e961","DOI":"10.1016\/j.clml.2020.07.015","article-title":"Modified hyper-CVAD with proteasome inhibition for multiple myeloma: a single-center retrospective analysis","volume":"20","author":"Narayan","year":"2020","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"2","key":"10.1016\/j.jtct.2024.05.016_bib0024","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1002\/ajh.24954","article-title":"Efficacy of VDT PACE-like regimens in treatment of relapsed\/refractory multiple myeloma","volume":"93","author":"Lakshman","year":"2018","journal-title":"Am J Hematol"},{"issue":"11","key":"10.1016\/j.jtct.2024.05.016_bib0025","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1016\/j.jtct.2022.08.017","article-title":"Successful mobilization of autologous hematopoietic peripheral blood stem cells after salvage chemotherapy in patients with low CD34 blood cell counts","volume":"28","author":"Holmberg","year":"2022","journal-title":"Transplant Cell Ther"},{"issue":"8","key":"10.1016\/j.jtct.2024.05.016_bib0026","doi-asserted-by":"crossref","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","article-title":"International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma","volume":"17","author":"Kumar","year":"2016","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.jtct.2024.05.016_bib0027","doi-asserted-by":"crossref","first-page":"7","DOI":"10.21037\/atm.2016.08.57","article-title":"Propensity score method: a non-parametric technique to reduce model dependence","volume":"5","author":"Zhang","year":"2017","journal-title":"Ann Transl Med"},{"issue":"1","key":"10.1016\/j.jtct.2024.05.016_bib0028","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1080\/00273171.2011.540475","article-title":"A systematic review of propensity score methods in the social sciences","volume":"46","author":"Thoemmes","year":"2011","journal-title":"Multivariate Behav Res"},{"issue":"3","key":"10.1016\/j.jtct.2024.05.016_bib0029","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1007\/s00068-017-0786-6","article-title":"A systematic review of propensity score methods in the acute care surgery literature: avoiding the pitfalls and proposing a set of reporting guidelines","volume":"44","author":"Zakrison","year":"2018","journal-title":"Eur J Trauma Emerg Surg"},{"issue":"467","key":"10.1016\/j.jtct.2024.05.016_bib0030","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1198\/016214504000000647","article-title":"Full matching in an observational study of coaching for the SAT","volume":"99","author":"Hansen","year":"2004","journal-title":"J Am Stat Assoc"},{"issue":"2","key":"10.1016\/j.jtct.2024.05.016_bib0031","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1037\/0012-1649.44.2.395","article-title":"Using full matching to estimate causal effects in nonexperimental studies: examining the relationship between adolescent marijuana use and adult outcomes","volume":"44","author":"Stuart","year":"2008","journal-title":"Dev Psychol"},{"issue":"3","key":"10.1016\/j.jtct.2024.05.016_bib0032","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1111\/j.2517-6161.1991.tb01848.x","article-title":"A characterization of optimal designs for observational studies","volume":"53","author":"Rosenbaum","year":"2018","journal-title":"J R Stat Soc: Series B"},{"issue":"12","key":"10.1016\/j.jtct.2024.05.016_bib0033","doi-asserted-by":"crossref","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","article-title":"International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma","volume":"15","author":"Rajkumar","year":"2014","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.jtct.2024.05.016_bib0034","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1214\/09-STS313","article-title":"Matching methods for causal inference: a review and a look forward","volume":"25","author":"Stuart","year":"2010","journal-title":"Stat Sci"}],"container-title":["Transplantation and Cellular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636724004135?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636724004135?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T02:15:52Z","timestamp":1754014552000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666636724004135"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8]]},"references-count":34,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["S2666636724004135"],"URL":"https:\/\/doi.org\/10.1016\/j.jtct.2024.05.016","relation":{},"ISSN":["2666-6367"],"issn-type":[{"value":"2666-6367","type":"print"}],"subject":[],"published":{"date-parts":[[2024,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Optimizing Autologous Stem Cell Transplantation in Multiple Myeloma: The Impact of Intensive Chemomobilization","name":"articletitle","label":"Article Title"},{"value":"Transplantation and Cellular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtct.2024.05.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}